<p>Several pathologies with metabolic origin, such as hyperuricemia and gout, have been associated with the gut microbiota taxonomic profile. However, there is no evidence of which bacterial genes are being expressed in the gut microbiome, and of their potential effects on hyperuricemia and gout. We sequenced the RNA of 26 fecal samples from 10 healthy normouricemic controls, 10 with asymptomatic hyperuricemia (AH), and six gout patients. The coding sequences were mapped to KEGG orthologues (KO). We compared the expression levels using generalized linear models and validated the expression of four KO in a larger sample by qRT-PCR. A distinct genetic expression pattern was identified among groups. AH individuals and gout patients showed an over-expression of KOs mainly related to pyruvate metabolism (Log2foldchange &gt; 23, <i>p</i>-adj ≤ 3.56 × 10<sup>− 9</sup>), the pentose pathway (Log2foldchange &gt; 24, <i>p</i>-adj &lt; 1.10 × 10<sup>−12</sup>) and purine metabolism (Log2foldchange &gt; 22, <i>p</i>-adj &lt; 1.25 × 10<sup>− 7</sup>). AH subjects had lower expression of KO related to glycine metabolism (Log2foldchange=-18, <i>p</i>-adj &lt; 1.72 × 10<sup>−6</sup>) than controls. Gout patients had lower expression (Log2foldchange=-22.42, <i>p</i>-adj &lt; 3.31 × 10<sup>− 16</sup>) of a KO involved in phenylalanine biosynthesis, in comparison to controls and AH subjects. The over-expression seen for the KO related to pyruvate metabolism and the pentose pathway in gout patients´ microbiome was validated. There is a differential gene expression pattern in the gut microbiome of normouricemic individuals, AH subjects and gout patients. These differences are mainly located in metabolic pathways involved in acetate precursors and bioavailability of amino acids.</p>

错误:搜索内容不能为空,请输入英文关键词
错误:关键词超出字数限制,请精简
高级检索

Metatranscriptomic analysis reveals gut microbiome bacterial genes in pyruvate and amino acid metabolism associated with hyperuricemia and gout in humans

  • Gabriela Angélica Martínez-Nava,
  • Efren Altamirano-Molina,
  • Janitzia Vázquez-Mellado,
  • Carlos S. Casimiro-Soriguer,
  • Joaquín Dopazo,
  • Carlos Lozada-Pérez,
  • Brígida Herrera-López,
  • Laura Edith Martínez-Gómez,
  • Carlos Martínez-Armenta,
  • Dafne Lissete Guido-Gómora,
  • Sarahí Valle-Gutiérrez,
  • Carlos Suarez-Ahedo,
  • María del Carmen Camacho-Rea,
  • Mireya Martínez-García,
  • Guadalupe Gutiérrez-Esparza,
  • Luis M. Amezcua-Guerra,
  • Yessica Zamudio-Cuevas,
  • Karina Martínez-Flores,
  • Javier Fernández-Torres,
  • Ana I. Burguete-García,
  • Yaneth Citlalli Orbe-Orihuela,
  • Alfredo Lagunas-Martínez,
  • Eder Orlando Méndez-Salazar,
  • Adriana Francisco-Balderas,
  • Berenice Palacios-González,
  • Carlos Pineda,
  • Alberto López-Reyes

摘要

Several pathologies with metabolic origin, such as hyperuricemia and gout, have been associated with the gut microbiota taxonomic profile. However, there is no evidence of which bacterial genes are being expressed in the gut microbiome, and of their potential effects on hyperuricemia and gout. We sequenced the RNA of 26 fecal samples from 10 healthy normouricemic controls, 10 with asymptomatic hyperuricemia (AH), and six gout patients. The coding sequences were mapped to KEGG orthologues (KO). We compared the expression levels using generalized linear models and validated the expression of four KO in a larger sample by qRT-PCR. A distinct genetic expression pattern was identified among groups. AH individuals and gout patients showed an over-expression of KOs mainly related to pyruvate metabolism (Log2foldchange > 23, p-adj ≤ 3.56 × 10− 9), the pentose pathway (Log2foldchange > 24, p-adj < 1.10 × 10−12) and purine metabolism (Log2foldchange > 22, p-adj < 1.25 × 10− 7). AH subjects had lower expression of KO related to glycine metabolism (Log2foldchange=-18, p-adj < 1.72 × 10−6) than controls. Gout patients had lower expression (Log2foldchange=-22.42, p-adj < 3.31 × 10− 16) of a KO involved in phenylalanine biosynthesis, in comparison to controls and AH subjects. The over-expression seen for the KO related to pyruvate metabolism and the pentose pathway in gout patients´ microbiome was validated. There is a differential gene expression pattern in the gut microbiome of normouricemic individuals, AH subjects and gout patients. These differences are mainly located in metabolic pathways involved in acetate precursors and bioavailability of amino acids.